Latest studies
- Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseNorway - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerNorway - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)
This study is testing a new medicine called Tozorakimab for people with severe COPD. It aims to see if Tozorakimab can reduce flare-ups and is safe to use long-term, compared to a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
This study looks at a new treatment for advanced melanoma that has not responded to previous immunotherapy. It combines an injected drug (LTX-315) with an existing cancer drug (Pembrolizumab) to see if it can shrink tumours and extend life. Researchers will closely monitor participants' health.
Advanced MelanomaNorway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2B, multicenter, randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of HRO350 in subjects with mild-to-moderate psoriasis (the ‘HeROPA’ study)
This study is testing a new treatment called HRO350 for people with mild to moderate psoriasis. Researchers want to see if it improves psoriasis symptoms and is safe to use. Some people will get HRO350, others will get a dummy treatment, to compare results over 26 weeks. It's for adults aged 18 and over.
PsoriasisNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS9: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with high 'triglycerides' (a type of fat in the blood) and heart problems. It aims to see if the medicine can lower these fats and is safe to use.
Hypertriglyceridemia, Cardiovascular Diseases, AtherosclerosisNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
This study is testing a new medicine, secukinumab, for polymyalgia rheumatica (PMR). It compares secukinumab with a dummy treatment (placebo) alongside a common steroid medicine to see if it helps reduce symptoms and allows people to use less steroid medicine.
Polymyalgia RheumaticaNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Intermittent ibrutinib in chronic lymphocytic leukemia
This study is looking at a new way to give a medicine called ibrutinib for chronic lymphocytic leukaemia (CLL). Instead of taking the medicine all the time, patients will take it in cycles, with breaks in between. This is an early study to see how safe and effective this new approach is.
Chronic lymphocytic leukemiaNorway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
This study looks at a new drug called daratumumab to see if it can stop a high-risk precancerous blood condition, called smouldering multiple myeloma, from turning into a more serious cancer. It compares the drug to close observation to see which approach works best.
Precancerous form of blood cancer in the bone marrowNorway - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC)
This study is looking at how a new medicine, called norucholic acid (NCA), moves through the bodies of people with primary sclerosing cholangitis (PSC). It's an early stage study to understand the medicine better.
Primary Sclerosing Cholangitis (PSC)Norway - Ongoing, recruitingTherapeutic confirmatory (Phase III)
C5721002 _ A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
This study is testing a new drug (Tisotumab Vedotin) for cervical cancer that has come back or spread, and hasn't responded to previous treatments. It compares whether the new drug works better than standard chemotherapy to help people live longer.
Second- or Third-Line Recurrent or Metastatic Cervical CancerNorway - Enrolling by invitationPHASE2
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
This study looks at a medicine called Infigratinib for children and teenagers aged 3-18 with achondroplasia, a type of dwarfism. It's an ongoing study to check the medicine's safety, how well it works, and its long-term effects on growth and quality of life.
AchondroplasiaNorway - Active not recruiting
Micra Transcatheter Pacing System Post-Approval Registry
This study is looking at how a tiny pacemaker, the Micra Transcatheter Pacing System, works in everyday life after it's been approved. It's for people who need this type of pacemaker due to a slow heart rate (bradycardia) to check its safety and how well it works over time.
BradycardiaNorway - RecruitingPHASE2, PHASE3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This study keeps an eye on people who have had a special treatment called gene-modified T-cell therapy for cancer. It aims to check their health and how well the treatment worked over a long time, making sure it's safe and effective.
NeoplasmsNorway - Active not recruitingPHASE2
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This study is testing a new drug called batoclimab for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see how well it works and if it's safe compared to a dummy drug.
Chronic Inflammatory Demyelinating PolyneuropathyNorway - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer MetastaticNorway - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
Colorectal NeoplasmsNorway - RecruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
Multiple MyelomaNorway - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
Carcinoma, Non-Small-Cell LungNeoplasm MetastasisNorway - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersNorway - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseNorway - Active not recruiting
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This study looks at the long-term effects of a medicine called Humira for adults with a bowel condition called ulcerative colitis. It aims to see how well Humira works and if it's safe over a long time when used as doctors usually prescribe it.
Ulcerative Colitis (UC)Norway - Active not recruitingPHASE3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, apalutamide, for men with prostate cancer that hasn't spread but is resistant to standard treatment. It aims to see if the drug can stop the cancer from spreading and if it's safe to use.
Prostatic NeoplasmsNorway - RecruitingPHASE3
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study looks at a new treatment called benralizumab for people with severe asthma. It compares adding benralizumab to your usual asthma inhaler with just increasing the dose of your inhaler. We want to see if benralizumab helps control asthma better and is safe.
Eosinophilic AsthmaNorway - Active not recruitingPHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This study is for men with prostate cancer who are already taking enzalutamide as part of another research study. It aims to gather more information on the long-term safety of enzalutamide when it's helping them. Participants will continue their current treatment and have regular check-ups.
Prostate CancerNorway - Active not recruitingPHASE3
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
This study looks at a new drug, vimseltinib, for a condition called Tenosynovial Giant Cell Tumor (TGCT) when surgery isn't possible. It compares vimseltinib to a dummy drug for 24 weeks, then everyone gets the real drug. It aims to see how well it shrinks tumors.
Tenosynovial Giant Cell TumorPigmented Villonodular SynovitisGiant Cell Tumor of Tendon SheathTenosynovial Giant Cell Tumor, DiffuseNorway - RecruitingPHASE3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
This study looks at a new treatment called dostarlimab for certain types of colon cancer that haven't spread. It compares dostarlimab with standard treatments to see if it works better before and after surgery to help patients.
Colonic NeoplasmsNeoplasms, ColonNorway - Active not recruitingPHASE3
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
This study is looking at a new medicine called Tezepelumab for people aged 12-80 with Eosinophilic Oesophagitis (EoE). It aims to see if regular injections help improve symptoms and is safe, compared to a dummy treatment.
Eosinophilic EsophagitisNorway - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesNorway - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy after surgery for certain types of womb cancer (endometrial cancer). We want to see if this combination helps stop the cancer from coming back and helps people live longer compared to chemotherapy alone.
Endometrial NeoplasmsNorway - RecruitingNA
Beyond TME Origins
This study looks at a new way to classify advanced bowel cancer that has come back in the pelvis. We’re using special scans to help doctors plan the best treatment and understand why cancer might return, ultimately aiming to improve care.
NeoplasmsAdenocarcinomaCarcinomaNorway - RecruitingPHASE3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
This study is looking at a new medicine called nipocalimab for adults with moderate to severe lupus. It compares nipocalimab to a dummy treatment (placebo) to see if it can help reduce inflammation and improve lupus symptoms.
Lupus Erythematosus, SystemicNorway - Active not recruitingPHASE3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This study compares a new cancer drug called sigvotatug vedotin with a standard treatment, docetaxel, for advanced non-small cell lung cancer that has previously been treated. It aims to see if the new drug works better and what side effects it might cause.
Carcinoma, Non-Small-Cell LungNorway - Active not recruitingPHASE3
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
This study is looking into a new combination treatment (Zibotentan/Dapagliflozin) for chronic kidney disease with high protein levels in the urine. It compares this combination with an existing treatment (Dapagliflozin) to see if it's more effective and safe.
Chronic Kidney Disease With High ProteinuriaNorway - Active not recruiting
Validation and Standardization of Paramagnetic Rim Lesion (PRL) Identification in Multiple Sclerosis Across MAGNIMS Centers
This study looks at how consistently special brain scans (MRIs) are read across different hospitals for people with Multiple Sclerosis (MS). It aims to make sure everyone agrees on identifying specific 'rim lesions' in MS to help improve diagnosis and treatment plans for patients, using existing scan data only.
Multiple SclerosisNorway - Active not recruitingNA
Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation
This study looks at how premature babies, born between 28 and 32 weeks, respond to skin-to-skin contact with their mothers right after birth. Researchers will compare babies who have skin-to-skin with those who go into an incubator, checking their body functions and movements to see if skin-to-skin makes a difference.
Premature BirthNorway - Enrolling by invitationPHASE1
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This study is looking at a new treatment called RAY121 for people with certain immune conditions like lupus-like disorders, skin blistering, or blood problems. It's a long-term follow-up for people who did well in an earlier study, to see how RAY121 works over time and if it continues to help.
Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Behçet's Syndrome (BS)Dermatomyositis (DM)Norway - AuthorisedTherapeutic confirmatory (Phase III)
TENACITY – A Phase III, prospective, randomized, open-label, blinded endpoint assessment (PROBE) to assess efficacy and safety of i.v. tenecteplase vs standard of care in patients with acute ischemic stroke (including wake-up stroke), last known well >4.5 h with imaging evidence of salvageable ischemic tissue
This study is looking at a new way to treat people who have had a stroke caused by a blood clot. It compares a drug called tenecteplase with the usual care, especially for those treated later or who wake up with stroke symptoms.
Acute Ischemic StrokeNorway - AuthorisedTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and quality of life outcomes of Vi-Siblin in patients with low anterior resection syndrome following rectal cancer surgery.
This study looks at whether a fibre supplement called Vi-Siblin can help people who have bowel problems (Low Anterior Resection Syndrome, or LARS) after surgery for rectal cancer. It compares Vi-Siblin to a dummy powder to see if it improves symptoms and quality of life.
Low anterior resection syndrome after low anterior resection for rectal cancerNorway - RecruitingPHASE2
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
This study looks at new medications for adults with moderate to severe Crohn's disease. Researchers want to see how well these 'targeted therapies' work and if they cause side effects, to find better ways to manage the condition.
Crohn's DiseaseNorway - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This study looks at the everyday safety and how well a drug called tolebrutinib is tolerated over a long time. It's for adults with different types of multiple sclerosis (MS) who have already been in earlier tolebrutinib studies.
Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisNorway - AuthorisedTherapeutic confirmatory (Phase III)
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
This study looks at a new drug, obrixtamig, alongside usual treatment for extensive small cell lung cancer. It aims to see if this new combination helps people live longer and feel better compared to the usual treatment alone.
small cell lung cancerNorway - RecruitingPHASE3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
This study looks at a new drug called venetoclax for children, teenagers, and young adults with acute myeloid leukaemia (AML) that has come back. It aims to see if adding venetoclax to standard chemotherapy can help improve their chances of survival.
Acute Myeloid LeukemiaNorway - AuthorisedTherapeutic confirmatory (Phase III)
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
This study is comparing a new medicine called Pumitamig with a standard treatment, Pembrolizumab, for a type of lung cancer. Researchers want to see if Pumitamig can stop cancer from growing for longer or help people live longer than current treatment.
Non-Small Cell Lung CancerNorway - RecruitingPHASE1, PHASE2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
This study looks for new ways to treat advanced oesophageal cancer that has spread or can't be removed by surgery. It combines existing immunotherapy (pembrolizumab) with new experimental drugs, sometimes with chemotherapy. The main goal is to check safety and how well these treatments work.
Esophageal Squamous Cell CarcinomaNorway - Active not recruitingPHASE2
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
This study is testing a new medicine, Claseprubart (also called DNTH103), for adults with a condition called generalized myasthenia gravis (gMG). We want to see if the medicine is safe, well-tolerated, and helps improve symptoms. Some people will get the new medicine, and others a placebo.
Myasthenia Gravis, GeneralizedNorway - RecruitingPHASE3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
This study investigates if a drug called baricitinib can protect the body's insulin-making cells in children and adults newly diagnosed with type 1 diabetes. It aims to see if preserving these cells helps manage the condition better.
Diabetes Mellitus, Type 1Norway - RecruitingPHASE3
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
This study is testing a new medicine, nipocalimab, to see if it can help prevent a serious blood condition called FNAIT in babies. FNAIT can cause low platelet counts in newborns, which can lead to bleeding problems. Researchers want to know if nipocalimab is effective and safe.
Thrombocytopenia, Neonatal AlloimmuneNorway - Recruiting
Effects of Oncological Treatment During Pregnancy on Mother and Child
This study looks at how cancer and its treatments during pregnancy affect mums and their babies. Researchers want to see if babies exposed to treatments like chemotherapy develop normally, and they'll also track the mothers' health.
CancerPregnancyNorway